Immune-Onc ratchets up a series B1 and B2 for $73M

Mar 30

Written By Mollie Rotmensch

Mollie Rotmensch

LLS TAP Announces Five New Investments Supporting Next Generation Immunotherapies

Going head-to-head with Merck on I/O, Genentech vets raise fresh round and enter clinic